+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Biologics Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4828093
  • Report
  • March 2019
  • Region: Global
  • 120 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • AbbVie Inc.
  • Amgen, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • MORE
Market Overview

The biologics market is majorly driven by growing capital investment from the key market players, the rise in the prevalence of chronic diseases, loss of patent exclusivity of the leading biologic drugs, and growing demand and higher acceptability for innovative therapies

The success of biologic drugs in the treatment of major chronic diseases, notably cancer and autoimmune diseases, has enabled big pharmaceutical companies, like Eli Lilly and Company, Bristol-Myers Squibb, Novartis, AstraZeneca, and GlaxoSmithKline (GSK), to invest in these products. In 2016, biologics accounted for six of the top-eight drugs, in terms of revenue. Humira (adalimumab), which was developed by AbbVie for the treatment of rheumatoid arthritis, psoriasis, Crohn’s, and other autoimmune diseases, led to USD 16 billion in sales, as per the report, Top 15 Best-Selling Drugs of 2016. Humira was also the fastest growing biological drug. Amgen and Pfizer developed Enbrel, which is used for treating polyarticular juvenile idiopathic arthritis in patients aged two years or older and plaque psoriasis in patients aged four years or older. Novartis AG invested around USD 700 million in its biologics facility in Singapore, and Bristol-Myers Squibb invested nearly USD 900 million in an Irish large-scale biologics facility that is anticipated to be completed by 2019.

Furthermore, the companies are either acquiring or merging with other companies, for significant deals. For instance, Shire acquired Baxalta to create a biologics-based product for the treatment of rare diseases and other specialized disorders. Pfizer bought Medivation mainly due to the prostate cancer drug Xtandi. Pfizer also acquired Anacor Pharma­ceuticals to strengthen its inflammation and immunology pipeline. Thus, the growing expansion and investment in biologics by major companies are expected to lead to the continuing boom in biologics.

Scope of the Report

As per the scope of this report, the term biologic medicines refers to large, complex molecules that are made in living cells grown in a laboratory. Biologic medicines are often 200 to 1,000 times the size of a small molecule or chemical drug. Due to both their large molecular size and fragile molecular structure, biologic medicines are almost always injected into the patient’s body.

Key Market Trends

Vaccine Segment is Expected to Grow Fastest during the Forecast Period

The monoclonal antibodies segment held a maximum share in 2018 due to higher usage of this category of drugs in different therapeutic areas. mABs allow targeting of unhealthy cells without harming the healthy cells. Also, these drugs are used in the management and treatment of diseases, including cancer and autoimmune disorder.

Vaccines are expected to show significant growth during the forecast period due to the growing adoption of vaccines in the treatment of infectious diseases in the near future.

North America holds the Largest Market Share and is Believed to Follow the Same Trend over the Forecast Period

The North American healthcare biologics market dominated the global market and is estimated to show a similar trend during the forecast period. Factors augmenting the growth of biologics are increasing incidences of chronic diseases, the presence of well-established pharmaceutical companies, and an increase in the number of biotech companies. Furthermore, the presence of well-established companies, like Johnson & Johnson, Bristol-Myers Squibb, AbbVie Inc., and other key players, is making biologics more accessible in the United States. The US's Johnson & Johnson is in the lead, closely followed by the Swiss company Hoffman-La Roche. Government initiative for the awareness of biologics is further expected to spur the growth of the market in North America.

Competitive Landscape

The biologics market is moderately competitive and consists of several major players. The companies are implementing certain strategic initiatives, such as a merger, new product launch, acquisition, and partnerships that help them in strengthening their market position. For instance, in 2017 FDA approved GlaxoSmithKline’s biologic Nucala for the treatment of a rare disease called eosinophilic granulomatosis, with polyangiitis (EPGA).
Note: Product cover images may vary from those shown
2 of 4


  • AbbVie Inc.
  • Amgen, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Capital Investment from Key Market Players
4.2.2 Rise in the Prevalence of Chronic Diseases
4.2.3 Loss of Patent Exclusivity of the Leading Biologic Drugs
4.2.4 Growing Demand and Higher Acceptability for Innovative Therapies
4.3 Market Restraints
4.3.1 Stringent Regulatory Process and Initial High Capital Investment
4.3.2 Rising Control and Cost for Accessing Biologics
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product
5.1.1 Monoclonal Antibodies
5.1.2 Vaccines
5.1.3 Recombinant Hormones/Proteins
5.1.4 Cellular Based Biologics
5.1.5 Gene Based Biologics
5.1.6 Other Products
5.2 By Application
5.2.1 Cancer
5.2.2 Infectious Diseases
5.2.3 Rare Diseases
5.2.4 Autoimmune Diseases
5.2.5 Other Applications
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Amgen, Inc.
6.1.3 Eli Lilly and Company
6.1.4 F. Hoffmann-La Roche AG
6.1.5 GlaxoSmithKline PLC
6.1.6 Johnson & Johnson
6.1.7 Merck & Co.
6.1.8 Novo Nordisk A/S
6.1.9 Pfizer Inc.
6.1.10 Sanofi SA

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • AbbVie Inc.
  • Amgen, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
Note: Product cover images may vary from those shown